Schizophrenia & Psychosis: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• WorkshopClozapine Workshop

  Oliver Freudenreich

  Hands-on ticketed workshop on initiating, monitoring, and troubleshooting clozapine treatment.

  Clozapine

• LectureClozapine Basics

  Oliver Freudenreich

  Introductory overview of the fundamentals of using clozapine in clinical practice.

  Antipsychotic PrescribingClozapine

• LectureIs Adolescent Cannabis Use a Causal Factor for Schizophrenia?

  Eden Evins

  Examines the evidence on whether cannabis use during adolescence contributes causally to schizophrenia.

  Cannabis & CannabinoidsChild & Adolescent

• SessionProdromes, Early Detection and Prevention of Major Psychiatric Illnesses

  Daphne Holt

  Evening seminar on identifying and intervening in the earliest stages of serious mental illness.

  Serious Mental Illness

• LectureFirst-Episode Psychosis and Schizophrenia

  Oliver Freudenreich

  Early intervention and pharmacologic management of first-episode psychosis and schizophrenia.

  Antipsychotic Prescribing

See all 6 schizophrenia & psychosis sessions at this meeting →

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureSchizoaffective Disorders: Treatment Update

  Adrian Preda

  Current diagnostic and treatment considerations for schizoaffective disorder.

  Antipsychotic PrescribingBipolar Disorder

• LectureSchizophrenia: Treatment Update

  Rimal Bera

  An update on current schizophrenia pharmacotherapy.

  Antipsychotic Prescribing

• LectureOther Psychotic Disorders & Special Topics

  Rimal Bera

  Coverage of psychotic disorders beyond schizophrenia and selected special topics in psychosis care.

• LectureUpdate on Schizophrenia

  Rimal Bera

  Update on current understanding and management of schizophrenia.

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• SymposiumStuck at the Crossroads: Management of Treatment-Resistant Schizophrenia in Youth

  Henry Teaford · Brent Beck · Tatum Burdo · Shruti Tilak

  Clinical perspectives session on managing treatment-resistant schizophrenia in children and adolescents, including when and how to move to clozapine and other next-step strategies.

  Child & AdolescentClozapine

• LectureLarge Language Models: An Introduction for Clinicians and Application to Childhood Onset Psychosis

  Anthony Joseph Deo

  Introduces large language models to clinicians and illustrates their application to childhood-onset psychosis.

  Child & AdolescentDigital Psychiatry & AI

• LectureClozapine Augmentation With Antipsychotic and Nonantipsychotic Agents

  Brent Beck

  Covers strategies for augmenting clozapine with other antipsychotic and non-antipsychotic medications in youth with treatment-resistant schizophrenia.

  Child & AdolescentClozapine

• LectureChanging the Trajectory: Clozapine in Pediatric Treatment-Resistant Schizophrenia

  Tatum Burdo

  Discusses the role of clozapine in treating pediatric treatment-resistant schizophrenia and its effect on outcomes.

  Child & AdolescentClozapine

• LectureECT in Pediatric Treatment-Resistant Psychosis: Efficacy and Key Challenges

  Shruti Tilak

  Reviews the efficacy of ECT for treatment-resistant psychosis in young patients and the challenges involved.

  Child & AdolescentNeuromodulation (ECT, TMS)

See all 83 schizophrenia & psychosis sessions at this meeting →

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LectureTreating Stimulant Use Disorders: Where to Start

  Megan Hudson · Justin Alves · Ogo George · D'Arcy Gebert

  Practical starting points for stimulant use disorder care, including overamping, stimulant-induced psychosis, and medication options. Pharmacology-eligible.

  Substance Use Disorders

• SymposiumSuccessfully Transitioning to Long-Acting Injectable Antipsychotics in Schizophrenia

  Symposium breakfast covering LAI antipsychotic guidelines, shared decision-making, and hands-on injection technique via 3D simulation.

  Long-Acting Injectables

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumGaining Insight Into Anosognosia as a Barrier to Treatment of Schizophrenia Spectrum Disorders

  Stephen M. Stahl

  Examines impaired illness awareness in schizophrenia spectrum disorders and its impact on engagement and treatment adherence.

• SymposiumThe Clinical Promise of Muscarinic Agonists: Why, When, and How Across Neuropsychiatric Disorders

  Stephen M. Stahl

  Reviews the mechanism and clinical positioning of muscarinic agonists across neuropsychiatric conditions.

  Muscarinic & Novel Antipsychotics

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• Oral abstractShort-Term Clinical Outcomes in Early Psychosis with and without Recent Substance Use: The Role of Urine Drug Screening and Antipsychotics in an Urban Youth Cohort

  Chaden Noureddine

  Looks at short-term outcomes in youth with early psychosis by recent substance use, urine drug screening and antipsychotic use.

  Child & AdolescentSubstance Use Disorders

• PosterCannabis Use and Psychosis: A Case Series Highlighting Risk Factors for Schizophrenia-Spectrum Disorders.

  Emily Waller

  Case series on cannabis use and risk factors for schizophrenia-spectrum disorders.

  Cannabis & Cannabinoids

• PosterAssociation between Cannabis-Related Disorders and Incident Psychosis in Individuals with Adhd

  Christian Nolan

  Examines cannabis-related disorders and new psychosis among people with ADHD.

  ADHDCannabis & Cannabinoids

• PosterChildhood Trauma and Motives for Cannabis Use in Individuals with Psychosis

  Yousef Khan

  Links childhood trauma to motives for cannabis use in people with psychosis.

  Cannabis & CannabinoidsPTSD & Trauma

• PosterHigh-Potency Cannabis as a Modifiable Risk Factor for Cannabis-Induced Psychosis in Adolescents and Young Adults

  Sophia Azmi

  High-potency cannabis as a risk factor for psychosis in young people.

  Cannabis & CannabinoidsChild & Adolescent

See all 12 schizophrenia & psychosis sessions at this meeting →

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LecturePostpartum Mental Health: Beyond Depression

  Benicio N. Frey

  Postpartum psychiatric presentations beyond depression, including anxiety, OCD, and psychosis, and how to treat them.

  Anxiety DisordersOCD & Related DisordersPerinatal & Women's Mental Health

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• LectureE01 – Targeting the immune pathogenesis for the development of novel diagnostics and therapeutics of affective and non-affective psychosis

  Paolo Enrico · Rachel Upthegrove

  Educational update on immune-molecular patient stratification and multimodal inflammation measures in early psychosis.

  Inflammation & ImmunopsychiatryPharmacogenomics & Precision Psychiatry

• PlenaryPL02 – ECNP Neuropsychopharmacology Award Lecture – How will we get novel medicines in psychiatry? Lessons from schizophrenia

  Oliver Howes

  Award lecture drawing lessons from schizophrenia drug development for the broader pipeline of novel psychiatric medicines.

  Drug Pipeline & Clinical Trials

• SymposiumS06 – Retinal imaging in mental disorders: a novel lens on central nervous system dysfunction

  Steven Silverstein · Philipp Homan · Kathrin Nickel

  Retinal neural and microvascular changes as accessible windows on CNS dysfunction in psychosis and autism.

  Autism & Neurodevelopmental DisordersNeuroscience & Mechanisms

• SymposiumS15 – Novel Therapies Symposium – showcasing clinical trials on emerging compounds and new medical devices

  Lone Baandrup · Viktoria Damgaard · Daniel Umbricht · Susan L. Rossell · Alexandra Philipsen · Mikołaj Matłoka

  Trial results on emerging treatments including cannabidiol vs risperidone for cannabis-related psychosis (CANRISE), a novel oral NMDA antagonist, PDE10A inhibition in schizophrenia, and digital devices.

  Cannabis & CannabinoidsDrug Pipeline & Clinical Trials

• SymposiumMS04 – EAN Mini Symposium – Rethinking the psychiatric approach in neurology conditions: in case of movement disorders

  Anna Rita Bentivoglio · Jaime Kulisevsky

  Joint neurology session on psychiatric management in Huntington's disease and Parkinson's disease psychosis.

  Tardive Dyskinesia & Movement DisordersMedical Comorbidity & C-L Psychiatry

See all 6 schizophrenia & psychosis sessions at this meeting →

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• LecturePlenary Session 09 - Closing & Jean Delay Prize Lecture: Myelin and Schizophrenia: From a Better Phenotype to Drug Targets for Treatment

  Peter Falkai

  Award lecture on myelin pathology as a phenotype and treatment target in schizophrenia, closing the congress.

  Neuroscience & MechanismsDrug Pipeline & Clinical Trials

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• SymposiumMasterClass: Presynaptic Possibilities: The Past, Present, and Future of Modulating Dopamine

  Christoph U. Correll · Chelsie Monroe

  Covers presynaptic dopamine modulation in schizophrenia and bipolar I mania, including evidence for selective muscarinic agents and how to apply them to individual patients.

  Bipolar DisorderMuscarinic & Novel Antipsychotics

• SymposiumCannabis Use and Mental Illness: What We Now Know (and Don't)

  Ilan Melnick · Andrew Penn

  Updates clinicians on cannabis-induced psychosis, mood effects, and dose-response data amid rising THC potency, with practical tapering strategies and treatment pathways for cannabis use disorder.

  Cannabis & CannabinoidsSubstance Use Disorders

• SymposiumNot All Delusions are Schizophrenia: Understanding Delusional Disorders and the Overlap with Substance Induced Psychosis

  Arwen Podesta · Andrew Penn

  Uses a historic case to teach differential diagnosis of psychosis beyond schizophrenia — substance-induced, delusional, and medical causes — including temporal analysis, labs, and imaging.

  Measurement-Based Care & DiagnosisSubstance Use Disorders

• SymposiumDeprescribing Definitions and Decisions Differ by Diagnosis: A Deep Dive for Bipolar & Schizophrenia Disorders

  Joseph Goldberg · Peter Weiden

  Compares how polypharmacy patterns and risk-benefit calculations shape deprescribing decisions differently in bipolar disorder versus schizophrenia.

  Bipolar DisorderDeprescribing & Polypharmacy

• SymposiumLatest Discoveries & Emerging Trends in Psychotic Disorders

  Christoph U. Correll · Ilan Melnick

  Fast-paced review of the year's most significant schizophrenia and psychosis research, with expert commentary and selected poster presenters sharing emerging data.

  Drug Pipeline & Clinical Trials

See all 9 schizophrenia & psychosis sessions at this meeting →